Literature DB >> 11771920

Use of propofol sedation in a pediatric emergency department: a prospective study.

E G Skokan1, C Pribble, K E Bassett, D S Nelson.   

Abstract

The purpose of this study was to determine the efficacy and safety of propofol sedation for pediatric procedures in the emergency department. For patients needing painful procedures, propofol was administered intravenously. Vital signs, complications, and time to recovery were recorded. Patient amnesia and parent, patient, and operator satisfaction with sedation were assessed. The mean age was 7.4 years; 65% were male. Most underwent fracture reduction. Mean total dose was 3.3 mg/kg. Thirty percent experienced desaturation. One required assisted ventilation. Most had decreases in blood pressure. Mean recovery time was 18 minutes. Satisfaction with sedation was rated "excellent." Propofol was an effective sedation with minimal complications in the emergency department setting.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11771920     DOI: 10.1177/000992280104001204

Source DB:  PubMed          Journal:  Clin Pediatr (Phila)        ISSN: 0009-9228            Impact factor:   1.168


  4 in total

Review 1.  A review of the use of propofol for procedural sedation in the emergency department.

Authors:  L Symington; S Thakore
Journal:  Emerg Med J       Date:  2006-02       Impact factor: 2.740

2.  Use of propofol sedation in the paediatric emergency department.

Authors:  Peggy Chang; David Warren; Gary Joubert; Michael Rieder
Journal:  Paediatr Child Health       Date:  2003-10       Impact factor: 2.253

Review 3.  Emergency department management of pain and anxiety related to orthopedic fracture care: a guide to analgesic techniques and procedural sedation in children.

Authors:  Robert M Kennedy; Jan D Luhmann; Scott J Luhmann
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

4.  A Novel Propofol Dosing Regimen for Pediatric Sedation during Radiologic Tests.

Authors:  Ji-Young Min; Jeong-Rim Lee; Hye-Mi Lee; Ho-Jae Nam; Hyo-Jin Byon
Journal:  J Clin Med       Date:  2022-08-29       Impact factor: 4.964

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.